STRATEC SE

Board/Management Information • Feb 8, 2011

News Details

Corporate | 8 February 2011 08:51

Wolfgang Wehmeyer appointed to Supervisory Board of STRATEC Biomedical Systems AG

STRATEC Biomedical Systems AG / Key word(s): Change of Personnel

08.02.2011 / 08:51

Wolfgang Wehmeyer appointed to Supervisory Board of STRATEC Biomedical
Systems AG

Birkenfeld, February 8, 2011

STRATEC Biomedical Systems AG, Birkenfeld, Germany (Frankfurt: SBS; Prime
Standard, TecDAX) today announced that the Mannheim District Court has, by
resolution dated January 21, 2011, approved the petition of January 3, 2011
submitted by the Board of Management of STRATEC Biomedical Systems AG and
in so doing has appointed Wolfgang Wehmeyer as a member of the Company's
Supervisory Board.

This court appointment was necessitated by Dr. Robert Siegle stepping down
from his Supervisory Board position as of December 31, 2010 in preparation
for his move to the Board of Management of STRATEC Biomedical Systems AG on
February 1, 2011. The appointment of Wolfgang Wehmeyer is expected to be
confirmed at the Company's forthcoming Annual General Meeting on April 14,
2011.

Wolfgang Wehmeyer has been Senior Vice President for International
Marketing & Medicine at the DAX-listed group Fresenius Medical Care since
2004 and will remain in this role. He has more than 20 years' experience in
medical technology, where he has held positions in the fields of production
automation, product development, sales company management, and
international marketing.

About STRATEC

STRATEC Biomedical Systems AG (www.stratec.com) designs and manufactures
fully automated systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, to laboratories, blood banks and
research institutes around the world. The company develops its products on
the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.

The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.

Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
ir@stratec.com
www.stratec.com

End of Corporate News

---

08.02.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

111384 08.02.2011